{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aricept", "query": { "intervention": "Aricept" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 151, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aricept&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T17:48:47.632Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00754052", "title": "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Down Syndrome", "Cognitive Dysfunction" ], "interventions": [ { "name": "Aricept (donepezil hydrochloride)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "11 Years to 17 Years" }, "enrollment_count": 8, "start_date": "2008-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2018-04-23", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 2, "location_summary": "San Antonio, Texas • Herndon, Virginia", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Herndon", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754052" }, { "nct_id": "NCT01120626", "title": "Randomized Controlled Study of Donepezil in Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "donepezil", "type": "DRUG" }, { "name": "sugar pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "12 Years to 29 Years" }, "enrollment_count": 45, "start_date": "2009-09", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01120626" }, { "nct_id": "NCT02918266", "title": "TAK-071 Scopolamine-Induced Cognitive Impairment Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Scopolamine", "type": "DRUG" }, { "name": "TAK-071", "type": "DRUG" }, { "name": "Donepezil", "type": "DRUG" }, { "name": "Scopolamine Placebo", "type": "DRUG" }, { "name": "TAK-071 Placebo", "type": "DRUG" }, { "name": "Donepezil Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 18, "start_date": "2016-11-21", "completion_date": "2017-08-08", "has_results": true, "last_update_posted_date": "2019-06-14", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02918266" }, { "nct_id": "NCT03259958", "title": "A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Donepezil TDS", "type": "DRUG" }, { "name": "Aricept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 86, "start_date": "2017-10-30", "completion_date": "2018-03-14", "has_results": false, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03259958" }, { "nct_id": "NCT02264353", "title": "The Impact of Arousal Threshold in Obstructive Sleep Apnea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obstructive Sleep Apnea" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 44, "start_date": "2014-09", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-08-08", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02264353" }, { "nct_id": "NCT00104273", "title": "Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dementia", "Alzheimer's Disease" ], "interventions": [ { "name": "Rasagiline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "45 Years to 90 Years" }, "enrollment_count": 376, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-07-15", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104273" }, { "nct_id": "NCT04505670", "title": "The Effect of Donepezil on Wound Healing", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wound Heal" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" }, { "name": "Topical Zinc Oxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 20, "start_date": "2020-08-30", "completion_date": "2023-07-30", "has_results": false, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Easton, Maryland", "locations": [ { "city": "Easton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505670" }, { "nct_id": "NCT01276080", "title": "Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2009-10", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2012-07-10", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276080" }, { "nct_id": "NCT02670161", "title": "Quality Improvement and Practice Based Research in Neurology Using the EMR", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Brain Tumors", "Epilepsy", "Migraine", "Mild Cognitive Impairment", "Concussion", "Multiple Sclerosis", "Neuropathy", "Parkinson's", "Restless Legs Syndrome", "Stroke" ], "interventions": [ { "name": "Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endeavor Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 3300, "start_date": "2016-05", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Evanston, Illinois", "locations": [ { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02670161" }, { "nct_id": "NCT00711204", "title": "Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Severe Alzheimer's Disease" ], "interventions": [ { "name": "Donepezil Hydrochloride (Aricept)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 0, "start_date": "2008-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-12-10", "last_synced_at": "2026-09-04T17:48:47.632Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711204" } ] }